5 results
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
The study will excist of two experiments. The first experiment is a two week overnight electrical stimulation program and in the second experiment subjects will be stimulated for 4 months.With these two experiments we wish to answer the following…
Study the effectiveness and safety of LAAO in non-valvular AF patients at high stroke risk unable to use OAC